<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Adres</title>
	<atom:link href="https://adreshe.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://adreshe.com/</link>
	<description>Health Economics &#38; Outcomes Research</description>
	<lastBuildDate>Thu, 04 Dec 2025 17:35:33 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://adreshe.com/wp-content/uploads/2024/06/cropped-Logo-Ad-32x32.png</url>
	<title>Adres</title>
	<link>https://adreshe.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy</title>
		<link>https://adreshe.com/cost-minimization-analysis-and-budget-impact-analysis-about-subcutaneous-natalizumab-in-relapsing-remitting-multiple-sclerosis-in-italy/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 04 Dec 2025 17:35:30 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5561</guid>

					<description><![CDATA[<p>Pradelli L, Heller AR, Klek S, Mayer K, Rosenthal MD, Muscaritoli M. Clinicoecon Outcomes Res. 2025 Apr 11:17:315-333</p>
<p>L'articolo <a href="https://adreshe.com/cost-minimization-analysis-and-budget-impact-analysis-about-subcutaneous-natalizumab-in-relapsing-remitting-multiple-sclerosis-in-italy/">Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Heller AR, Klek S, Mayer K, Rosenthal MD, Muscaritoli M. Clinicoecon Outcomes Res. 2025 Apr 11:17:315-333</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/cost-minimization-analysis-and-budget-impact-analysis-about-subcutaneous-natalizumab-in-relapsing-remitting-multiple-sclerosis-in-italy/">Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Parenteral Nutrition Containing Fish Oil for Hospitalized Non-Intensive Care Unit (ICU) Patients: A Systematic Review, Meta-Analysis, and Cost-Effectiveness Analysis</title>
		<link>https://adreshe.com/parenteral-nutrition-containing-fish-oil-for-hospitalized-non-intensive-care-unit-icu-patients-a-systematic-review-meta-analysis-and-cost-effectiveness-analysis/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 04 Dec 2025 17:18:12 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5558</guid>

					<description><![CDATA[<p>Pradelli L, Heller AR, Klek S, Mayer K, Rosenthal MD, Muscaritoli M. 2025 Apr 7;17(7):1284.</p>
<p>L'articolo <a href="https://adreshe.com/parenteral-nutrition-containing-fish-oil-for-hospitalized-non-intensive-care-unit-icu-patients-a-systematic-review-meta-analysis-and-cost-effectiveness-analysis/">Parenteral Nutrition Containing Fish Oil for Hospitalized Non-Intensive Care Unit (ICU) Patients: A Systematic Review, Meta-Analysis, and Cost-Effectiveness Analysis</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Pradelli L, Heller AR, Klek S, Mayer K, Rosenthal MD, Muscaritoli M. 2025 Apr 7;17(7):1284. </p>
<p>L'articolo <a href="https://adreshe.com/parenteral-nutrition-containing-fish-oil-for-hospitalized-non-intensive-care-unit-icu-patients-a-systematic-review-meta-analysis-and-cost-effectiveness-analysis/">Parenteral Nutrition Containing Fish Oil for Hospitalized Non-Intensive Care Unit (ICU) Patients: A Systematic Review, Meta-Analysis, and Cost-Effectiveness Analysis</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cost-Effectiveness of a Ketoanalogue-supplemented Very Low-protein Diet in CKD.</title>
		<link>https://adreshe.com/cost-effectiveness-of-a-ketoanalogue-supplemented-very-low-protein-diet-in-ckd/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 04 Dec 2025 17:03:09 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5555</guid>

					<description><![CDATA[<p>Povero M, Simion T, Pradelli L. Nephrol Dial Transplant. 2025 Jul 8:gfaf123</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-a-ketoanalogue-supplemented-very-low-protein-diet-in-ckd/">Cost-Effectiveness of a Ketoanalogue-supplemented Very Low-protein Diet in CKD.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Povero M, Simion T, Pradelli L. Nephrol Dial Transplant. 2025 Jul 8:gfaf123</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-a-ketoanalogue-supplemented-very-low-protein-diet-in-ckd/">Cost-Effectiveness of a Ketoanalogue-supplemented Very Low-protein Diet in CKD.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy</title>
		<link>https://adreshe.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-treatment-of-third-or-higher-line-3l-relapsed-or-refractory-r-r-follicular-lymphoma-fl-in-italy/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 23 Oct 2025 13:14:15 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5552</guid>

					<description><![CDATA[<p>Luminari, S., Pinto, A., Puccini, B., D&#8217;Arpino, A., Omodeo Salè, E., Bellone, M., Pradelli, L., &#38; Sabinot, A. ClinicoEconomics and outcomes research : CEOR, 17, 335–348</p>
<p>L'articolo <a href="https://adreshe.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-treatment-of-third-or-higher-line-3l-relapsed-or-refractory-r-r-follicular-lymphoma-fl-in-italy/">A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Luminari, S., Pinto, A., Puccini, B., D&#8217;Arpino, A., Omodeo Salè, E., Bellone, M., Pradelli, L., &amp; Sabinot, A. <em>ClinicoEconomics and outcomes research : CEOR</em>, <em>17</em>, 335–348</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-treatment-of-third-or-higher-line-3l-relapsed-or-refractory-r-r-follicular-lymphoma-fl-in-italy/">A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy</title>
		<link>https://adreshe.com/cost-effectiveness-of-treatments-for-presymptomatic-newborn-patients-with-spinal-muscular-atrophy-and-two-or-three-copies-of-the-survival-motor-neuron-2-gene-in-italy/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 23 Oct 2025 13:10:55 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5550</guid>

					<description><![CDATA[<p>Valentini I, Ghetti G, Pane M, Rumi F, Di Brino E, Basile M, Pistillo GM, Bischof M. Eur J Health Econ. 2025 Jun 26</p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-treatments-for-presymptomatic-newborn-patients-with-spinal-muscular-atrophy-and-two-or-three-copies-of-the-survival-motor-neuron-2-gene-in-italy/">Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Valentini I, Ghetti G, Pane M, Rumi F, Di Brino E, Basile M, Pistillo GM, Bischof M. Eur J Health Econ. 2025 Jun 26</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/cost-effectiveness-of-treatments-for-presymptomatic-newborn-patients-with-spinal-muscular-atrophy-and-two-or-three-copies-of-the-survival-motor-neuron-2-gene-in-italy/">Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis</title>
		<link>https://adreshe.com/179p-genomic-profiling-in-hepatocellular-carcinoma-a-real-world-retrospective-analysis/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 23 Oct 2025 13:08:10 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5548</guid>

					<description><![CDATA[<p>F. Salani, F.R. Ponziani, F. Piscaglia, U. Malapelle, B. Daniele, C. Porta, L. Pradelli, E. De Fiore, G. Masi, L. Rimassa, A. Casadei Gardini. Annals of Oncology, Volume 36, S75 &#8211; S76</p>
<p>L'articolo <a href="https://adreshe.com/179p-genomic-profiling-in-hepatocellular-carcinoma-a-real-world-retrospective-analysis/">179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p> F. Salani, F.R. Ponziani, F. Piscaglia, U. Malapelle, B. Daniele, C. Porta, L. Pradelli, E. De Fiore, G. Masi, L. Rimassa, A. Casadei Gardini. Annals of Oncology, Volume 36, S75 &#8211; S76</p>
<p>L'articolo <a href="https://adreshe.com/179p-genomic-profiling-in-hepatocellular-carcinoma-a-real-world-retrospective-analysis/">179P Genomic profiling in hepatocellular carcinoma: A real-world retrospective analysis</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy</title>
		<link>https://adreshe.com/retifanlimab-vs-avelumab-in-patients-with-metastatic-merkel-cell-carcinoma-a-cost-utility-analysis-in-italy/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 13 Mar 2025 11:13:46 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5477</guid>

					<description><![CDATA[<p>Gianni Ghetti, Camilla Porta, Massimiliano Povero. Farmeconomia. Health economics and therapeutic pathways 2025; 26(1): 29-39</p>
<p>L'articolo <a href="https://adreshe.com/retifanlimab-vs-avelumab-in-patients-with-metastatic-merkel-cell-carcinoma-a-cost-utility-analysis-in-italy/">Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Gianni Ghetti, Camilla Porta, Massimiliano Povero. Farmeconomia. Health economics and therapeutic pathways 2025; 26(1): 29-39</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/retifanlimab-vs-avelumab-in-patients-with-metastatic-merkel-cell-carcinoma-a-cost-utility-analysis-in-italy/">Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Real-World Outcomes of Single-Inhaler Triple Therapy Prescribed by General Practitioners in Managing Chronic Obstructive Pulmonary Disease: A Systematic Literature Review</title>
		<link>https://adreshe.com/real-world-outcomes-of-single-inhaler-triple-therapy-prescribed-by-general-practitioners-in-managing-chronic-obstructive-pulmonary-disease-a-systematic-literature-review/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 06 Mar 2025 15:42:32 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5460</guid>

					<description><![CDATA[<p>Odonde L, Pradelli L, Micheletto C. Farmeconomia Health Econ Ther Pathw 2025; 26</p>
<p>L'articolo <a href="https://adreshe.com/real-world-outcomes-of-single-inhaler-triple-therapy-prescribed-by-general-practitioners-in-managing-chronic-obstructive-pulmonary-disease-a-systematic-literature-review/">Real-World Outcomes of Single-Inhaler Triple Therapy Prescribed by General Practitioners in Managing Chronic Obstructive Pulmonary Disease: A Systematic Literature Review</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p><em>Odonde L, Pradelli L, Micheletto C.</em> <em>Farmeconomia Health Econ Ther Pathw</em> 2025; 26</p>



<p></p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/real-world-outcomes-of-single-inhaler-triple-therapy-prescribed-by-general-practitioners-in-managing-chronic-obstructive-pulmonary-disease-a-systematic-literature-review/">Real-World Outcomes of Single-Inhaler Triple Therapy Prescribed by General Practitioners in Managing Chronic Obstructive Pulmonary Disease: A Systematic Literature Review</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.</title>
		<link>https://adreshe.com/the-clinical-impact-of-conventional-therapies-for-adults-and-adolescents-suffering-from-eosinophilic-esophagitis-a-type-2-inflammatory-chronic-disease-and-their-economic-consequences-in-italy-syste/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Tue, 04 Feb 2025 11:32:15 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5329</guid>

					<description><![CDATA[<p>Canonica GW, Mazziotti G, Repici A, et al. J Allergy Clin Immunol Glob 2025; 4;</p>
<p>L'articolo <a href="https://adreshe.com/the-clinical-impact-of-conventional-therapies-for-adults-and-adolescents-suffering-from-eosinophilic-esophagitis-a-type-2-inflammatory-chronic-disease-and-their-economic-consequences-in-italy-syste/">The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Canonica GW, Mazziotti G, Repici A, et al. <em>J Allergy Clin Immunol Glob 2025; 4; </em></p>
<p>L'articolo <a href="https://adreshe.com/the-clinical-impact-of-conventional-therapies-for-adults-and-adolescents-suffering-from-eosinophilic-esophagitis-a-type-2-inflammatory-chronic-disease-and-their-economic-consequences-in-italy-syste/">The clinical impact of conventional therapies for adults and adolescents suffering from eosinophilic esophagitis, a type 2 inflammatory chronic disease, and their economic consequences in Italy: Systematic literature review and meta-analysis.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Lipids in parenteral nutrition – expert consensus statements: translating guidelines into clinical practice.</title>
		<link>https://adreshe.com/lipids-in-parenteral-nutrition-expert-consensus-statements-translating-guidelines-into-clinical-practice/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Tue, 04 Feb 2025 11:30:19 +0000</pubDate>
				<category><![CDATA[2025]]></category>
		<category><![CDATA[ARTICOLI]]></category>
		<guid isPermaLink="false">https://adreshe.com/?p=5327</guid>

					<description><![CDATA[<p>Martindale RG, Calder PC, Cogle SV, et al. Clin Nutr Open Sci 2025; 0;</p>
<p>L'articolo <a href="https://adreshe.com/lipids-in-parenteral-nutrition-expert-consensus-statements-translating-guidelines-into-clinical-practice/">Lipids in parenteral nutrition – expert consensus statements: translating guidelines into clinical practice.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Martindale RG, Calder PC, Cogle SV, et al. <em>Clin Nutr Open Sci</em> 2025; 0;</p>



<p></p>
<p>L'articolo <a href="https://adreshe.com/lipids-in-parenteral-nutrition-expert-consensus-statements-translating-guidelines-into-clinical-practice/">Lipids in parenteral nutrition – expert consensus statements: translating guidelines into clinical practice.</a> proviene da <a href="https://adreshe.com">Adres</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
